NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Tacrolimus的中國市場:2021年∼2025年

Investigation Report on China's Tacrolimus Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1002611
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Tacrolimus的中國市場:2021年∼2025年 Investigation Report on China's Tacrolimus Market 2021-2025
出版日期: 2021年04月23日內容資訊: 英文 50 Pages
簡介

中國的Tacrolimus的銷售量在2016年∼2020年有增加趨勢。2016年至2020年的年複合成長率約為13.5%。2020年Tacrolimus在中國的銷售額為15.7億元人民幣。2020年與去年同期相比增長為4.8%,但由於COVID-19流行而與去年同期相比下降。

本報告提供中國的Tacrolimus市場相關調查分析,提供COVID-19的影響,銷售量·銷售數量,價格,市場預測等相關的系統性資訊。

目錄

第1章 Tacrolimus的相關概念

  • Tacrolimus的適應症
  • 中國的Tacrolimus的發展
  • 中國的Tacrolimus的政府核准
  • COVID-19對中國Tacrolimus銷售的影響

第2章 中國的Tacrolimus銷售

  • Tacrolimus的銷售量
    • 整體銷售量
    • 銷售量:各地區
  • Tacrolimus銷售數量
    • 本來銷售數量
    • 銷售數量:各地區
  • Tacrolimus的銷售量:中國的各劑型
    • 注射
    • 眼科用藥
    • 膠囊
    • 軟膏

第3章 中國的主要Tacrolimus製造商分析

  • 主要的Tacrolimus製造商市場佔有率分析
    • 市場佔有率:不同銷售額
    • 市場佔有率:銷售各數量
  • Astellas Pharma Co Ltd
  • Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
  • LEO Pharma A/S
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Sinopharm Chuankang Pharmaceutical Co., Ltd.

第4章 中國的各種製造商Tacrolimus的價格

  • Astellas Pharma Co Ltd (PROGRAF)
  • Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (Saifukai)
  • LEO Pharma A/S (PROTOPIC)
  • Zhejiang Hisun Pharmaceutical Co., Ltd. (Fumeixin)
  • Sinopharm Chuankang Pharmaceutical Co., Ltd. (Yilikang)

第5章 中國的Tacrolimus醫藥品市場預測

  • 中國的Tacrolimus市場發展的影響要素
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2104479

Tacrolimus is a macrolide antibiotic and is also a new immunosuppressant. It is available in a variety of dosage forms. The ointment is used for moderate to severe atopic dermatitis where traditional therapies are not suitable, while the capsule and the injection are used to prevent graft rejection after liver or kidney transplantation. In recent years, Tacrolimus has become the first-line medication for liver and kidney transplantation. The Tacrolimus eye drop is used for vernal keratoconjunctivitis with poor anti-allergic treatment.

Tacrolimus' original drug was developed by Fujisawa Pharmaceutical, which became Astellas after the merger. Tacrolimus was launched in China in 2005. In addition to Astellas, other manufacturers in the Chinese Tacrolimus market are Hangzhou Zhongmeihuadong, LEO, Zhejiang Hisun, and Sinopharm Chuankang.

According to CRI's market research, the sales value of Tacrolimus in China has an increasing trend from 2016 to 2020, with a CAGR of approximately 13.5% in 2016 to 2020. The sales revenue of Tacrolimus in China was CNY1.57 billion in 2020. The growth rate in 2020 was 4.8% Year on Year, which slowed down compared to that in the previous years due to the COVID-19 epidemic.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Tacrolimus will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to market expansion. In light of research findings, the indication for preventing rejection in transplantation operations generates most sales for Tacrolimus. However, the number of new dialysis patients each year far exceeds the number of organ transplant operations, which means the demand for transplantation is not satisfied. With the development of policies and the increase in the number of organ donations, more patients will be able to receive transplants in the future, which will increase the demand for Tacrolimus.

Topics covered:

  • The impact of COVID-19 on China's Tacrolimus market
  • Sales value and volume of China's Tacrolimus 2016-2020
  • Competitive landscape of China's Tacrolimus market
  • Prices of Tacrolimus in China
  • Prices of Tacrolimus in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Tacrolimus market
  • Prospect of China's Tacrolimus market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Tacrolimus

  • 1.1 Indications for Tacrolimus
  • 1.2 Development of Tacrolimus in China
  • 1.3 Governmental Approval of Tacrolimus in China
  • 1.4 The Impact of COVID-19 on Tacrolimus sales in China

2 Sales of Tacrolimus in China, 2016-2020

  • 2.1 Sales Value of Tacrolimus
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Tacrolimus
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Tacrolimus by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.2 Eye Drop
    • 2.3.3 Capsule
    • 2.3.4 Ointment (Cream)

3 Analysis of Major Tacrolimus Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Tacrolimus Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Astellas Pharma Co Ltd
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of PROGRAF (Astellas' Tacrolimus) in China
  • 3.3 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Saifukai (Hangzhou Zhongmeihuadong's Tacrolimus) in China
  • 3.4 LEO Pharma A/S
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of PROTOPIC (LEO's Tacrolimus) in China
  • 3.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Fumeixin (Zhejiang Hisun's Tacrolimus) in China
  • 3.6 Sinopharm Chuankang Pharmaceutical Co., Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Yilikang (Sinopharm Chuankang's Tacrolimus) in China

4 Prices of Tacrolimus for Different Manufacturers in China, 2020-2021

  • 4.1 Astellas Pharma Co Ltd (PROGRAF)
  • 4.2 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (Saifukai)
  • 4.3 LEO Pharma A/S (PROTOPIC)
  • 4.4 Zhejiang Hisun Pharmaceutical Co., Ltd. (Fumeixin)
  • 4.5 Sinopharm Chuankang Pharmaceutical Co., Ltd. (Yilikang)

5 Prospect of Chinese Tacrolimus drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Tacrolimus Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Tacrolimus Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Tacrolimus Registration in China
  • Chart Sales Value of Tacrolimus over the World
  • Chart Sales Value of Tacrolimus in China, 2016-2020
  • Chart Sales Value of Tacrolimus in China by Regions, 2016-2020
  • Chart Sales Volume of Tacrolimus in China, 2016-2020
  • Chart Sales Volume of Tacrolimus in China by Regions, 2016-2020
  • Chart Sales Value of Tacrolimus Injection in China, 2016-2020
  • Chart Sales Volume of Tacrolimus Injection in China, 2016-2020
  • Chart Sales Value of Tacrolimus Eye Drop in China, 2016-2020
  • Chart Sales Volume of Tacrolimus Eye Drop in China, 2016-2020
  • Chart Sales Value of Tacrolimus Capsule in China, 2016-2020
  • Chart Sales Volume of Tacrolimus Capsule in China, 2016-2020
  • Chart Sales Value of Tacrolimus Ointment (Cream) in China, 2016-2020
  • Chart Sales Volume of Tacrolimus Ointment (Cream) in China, 2016-2020
  • Chart Market Share by Sales Value of Top Tacrolimus Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of PROGRAF in China, 2016-2020
  • Chart Sales Value and Volume of Saifukai in China, 2016-2020
  • Chart Sales Value and Volume of PROTOPIC in China, 2016-2020
  • Chart Sales Value and Volume of Fumeixin, 2016-2020
  • Chart Sales Value and Volume of Yilikang, 2016-2020
  • Chart Referential Prices of PROGRAF in China, 2020-2021
  • Chart Referential Prices of Saifukai in China, 2020-2021
  • Chart Referential Prices of PROTOPIC in China, 2020-2021
  • Chart Referential Prices Fumeixin in China, 2020-2021
  • Chart Referential Prices Yilikang in China, 2020-2021
  • Chart Forecast on Sales Value of Tacrolimus in China, 2021-2025
  • Chart Forecast on Sales Volume of Tacrolimus in China, 2021-2025